RudaCure Inc., a company specializing in novel 药物开发, was selected for the Grand Prize at 'Core Innovation 韩国 2024' hosted by Kookmin Ilbo and Cookie News.
Unlike existing treatments, RudaCure developed a 干眼症治疗药 RCI001 that shortens drug exposure duration through excellent 泪液产生, 角膜损伤恢复, 抗炎, and 抗氧化 effects.
RCI001 demonstrates therapeutic effects within 24 weeks, and is recognized for overcoming the slow onset and 副作用 (充血, 出血, 眼内压升高, 灼热 upon 滴眼) of existing treatments. It also addresses the limitations of steroid-based treatments, enabling long-term use and resolving existing market discomfort.
RudaCure plans to complete domestic Phase 1 临床试验 by 2024, and conduct domestic and US Phase 2 临床试验 in 2025-2026. It also plans to actively pursue global 技术转让 through overseas 临床数据.
